Prion Protein as a Toxic Acceptor of Amyloid-β Oligomers by Collinge, J et al.
Page 1 of 28 
 
Prion protein as a toxic acceptor of amyloid-β oligomers 
Silvia A. Purro1, Andrew J. Nicoll1,2* and John Collinge1 * 
1 MRC Prion Unit at UCL, UCL Institute of Prion Diseases, Queen Square, London, WC1N 3BG. UK 
2 Elkington + Fife LLP, Prospect House, 8 Pembroke Road, Sevenoaks, Kent, TN13 1XR. UK 






Short title: PrPC as a toxic acceptor of Aβ oligomers 
Abstract: 120 words. 
Text: 4073 words. 
Tables: 1. 
Figures: 3. 
Supplementary material: 0. 
Key words: prion, amyloid, Alzheimer’s disease, oligomers, neurodegeneration, therapeutics. 
 
Page 2 of 28 
 
Abstract: 
The initial report that cellular prion protein (PrPC) mediates toxicity of Amyloid-β (Aβ) species linked 
to Alzheimer’s disease was initially treated with scepticism, but growing evidence supports this 
claim. That there is a high-affinity interaction is now clear and its molecular basis is being unravelled 
whilst recent studies have identified possible down-stream toxic mechanisms. Determination of the 
clinical significance of such interactions between PrPC and disease-associated Aβ species will require 
experimental medicine studies in humans. Compounds that inhibit PrP-dependent Aβ toxicity are 
starting to be trialled in humans and, although it is clear that only a fraction of Alzheimer’s disease 
toxicity could be governed by PrPC, a partial but still therapeutically useful role in human disease 
may soon be testable. 
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Introduction 
The pathological hallmarks of Alzheimer’s disease (AD) are extracellular deposition of cerebral 
amyloid predominantly composed of amyloid-β protein (Aβ) forming plaques and vascular deposits, 
and intracellular neurofibrillary tangles mainly composed of hyperphosphorylated Tau protein. Aβ 
plaques were initially suspected to be directly toxic to neurones, although closer inspection revealed 
that levels of plaque deposits did not necessarily correlate with the severity of disease (1). For this 
reason, attention has turned to soluble oligomeric forms of Aβ that appear to be more neurotoxic 
(2) and correlate better with disease in AD patients (3). The soluble Aβ forms range from monomers 
to high molecular weight aggregates with different properties and toxic effects (Figure 1). It is 
possible that distinct conformations or classes of assemblies may also possess different seeding 
activity (4;5). Similarities between Alzheimer’s and prion disease have been noted for decades and 
the recent major growth of interest in the role of so-called “prion-like” mechanisms in other 
neurodegenerative diseases has led to an explosion in publications linking these diseases (6), that 
are beyond the scope of this review. It remains to be seen if knowledge of the misfolding and seeded 
aggregation processes will result in new therapeutics for sporadic forms of these diseases. However, 
a wider understanding of prion pathogenesis and the decades of experience built up in the prion 
field could facilitate AD research and the development of novel therapies (7). 
AD itself incorporates a mêlée of genetic and apparently sporadic conditions that can co-exist with 
an ever greater number of co-pathologies as age-at-onset increases (8). The complexities of Aβ 
oligomer research have been discussed in detail elsewhere (9). Some arguments will be emphasised 
here, but all are relevant to this area of AD research. Poor reproducibility between labs is often 
blamed on poorly-defined synthetic preparations loosely based on standard “recipes” rather than 
fully characterising the content of each batch produced. This common assumption can only be 
tested if all preparations are fully characterised when published (9;10). A recent trend towards 
defining toxic Aβ assemblies by structural fingerprints, rather than the conditions in which they were 
produced, may help address this problem (11;12). As AD patient samples are both precious, and 
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inherently complex and heterogeneous, it seems pragmatic to continue to test a hypothesis with 
synthetic or recombinant Aβ that does not contain alternative APP metabolites before confirming 
the relevance with human samples (13). Indeed, Aβ samples from AD brain will always vary in 
composition, concentration and purity. Native isolation of different Aβ assemblies present in AD 
brain samples is complex, as purification methods can disrupt and change the conformation of 
aggregates (14). Identification of toxic receptors for such a heterologous disease will, of course, be 
challenging. 
In receptor binding terminology, both receptor and acceptor contain a receptive site for the ligand, 
although only the receptor induces a biological function. Moreover, the acceptor lacks an 
endogenous ligand. Many proteins have been described as “receptors” for toxic Aβ assemblies, 
implying a designed physiological function. It is possible that toxicity is linked to hijacking of a 
functional interaction with other Aβ assemblies, but until this is demonstrated the candidates are 
best described as “acceptors” for toxic Aβ assemblies. To date, the majority of research on the 
PrP:Aβ interaction has focused on the toxic signalling cascades rather than physiological or beneficial 
roles. Two possible functions of PrP as an Aβ receptor have been suggested: Firstly, as a facilitator of 
the low-density lipoprotein (LDL) - receptor-related protein-1 (LRP1) mediated Aβ monomer 
transcytosis out of the brain through the blood-brain barrier (BBB). Secondly, as a protector against 
Aβ-induced cell death by neutralising oligomeric Aβ (15-19). If the Aβ:PrP interaction has a function, 
it will no doubt unravel as we better understand the true physiological role of PrP (20). More 
research is needed to confirm the consequences of Aβ assemblies binding to PrP, as this will be 
crucial to develop new therapies targeting the interaction or its downstream effectors. 
Prion protein-mediated Aβ toxicity 
The Aβ oligomer as a ligand for prion protein  
Numerous macromolecules have been identified to bind to different forms of Aβ (9;21;22) – not 
surprising given the inherently sticky nature of this peptide in all forms from monomer through to 
amyloid plaques. A study by Lauren et al. (23) stood out because it used an unbiased cell-based 
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screen of all murine neuronal proteins to identify those that bound to a relatively well-defined 
preparation of Aβ, based on the “Amyloid-β-derived diffusible ligand” (ADDL) protocol (2). The only 
“hit” was prion protein (PrP). Not only was the interaction confirmed to occur at low nanomolar 
concentrations, PrP-knockout was also shown to prevent the toxic effect of Aβ in a measure of 
synaptic plasticity, long term potentiation (LTP). Incubation of nanomolar concentrations of Aβ with 
wild-type murine brain slices inhibited LTP, whereas in PrP-null mice LTP remained intact. Ironically, 
after years of effort to find specific, high affinity ligands for PrP, the interaction of PrP with Aβ was 
discovered from the opposite vantage point. Indeed, Aβ is perhaps the most widely-accepted high-
affinity binding partner for PrP. 
Confirming PrP-dependent toxicity in vivo 
A further study by the same group showed crossing a transgenic mouse model of AD that combines 
expression of mutant APPswe and presenilin-1 deltaE9 (PS1 ΔE9) (both from PrP promoters on a PrP-
null background) prevented pathological phenotypes such as neuronal loss and premature death 
whilst maintaining spatial learning and memory (24). Furthermore, a two-week peripheral treatment 
of another APP/PS1 mouse model (APPswePS1M146L both with Thy1 promoters) with the 6D11 
antibody increased the synaptic density in the hippocampus and improved spatial memory in a radial 
arm maze (25). 
Controversy and confirmation 
PrP-independent Aβ toxicity 
Following the initial report (23), a number of groups published seemingly contradictory reports. The 
first paper to cast doubt on the role of PrP in Aβ toxicity nevertheless confirmed a PrP:Aβ binding 
interaction (26). According to this study, PrPc is not required for Aβ-induced memory impairment in a 
novel object recognition test when synthetic Aβ oligomers are injected into the brains of mice. That 
PrP is not critical to all Aβ toxic readouts is not surprising and does not discount a role for this 
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protein in AD. However, this paper highlights an important point that not all Aβ toxicity is governed 
by PrP, even when the preparations are known to contain assemblies capable of interacting with 
PrP. Since the report of PrP as an Aβ oligomer acceptor, numerous other Aβ-interacting candidates 
have been suggested (see below). These have mainly been identified using a targeted approach 
rather than the unbiased binding screen used for PrP (23;27-34). Only by comparing the candidates 
side-by-side in the same assays can they be compared for their Aβ oligomer affinity and selectivity. 
Given that the PrP:Aβ interaction was reported first and the tools to study it are widely available 
within the molecular neuroscience community, it is not surprising that this interaction was quickly 
validated. Still, to date, PrP remains by far the most validated Aβ acceptor. 
Two studies described PrP-independent pathological, behavioural and electrophysiological changes 
in the APPPS1+ (APPswePS1L166P both with Thy1 promoters) (35) or J20 (APPswe/ind with PDGF-β 
promoter) (36) transgenic models. Potential PrP-specific reasons for these differences include the 
fact that some, but not all, models express APP using the PrP promoter and that PrP and APP 
processing may be interrelated (37). The contrasting findings might also be the result of differences 
in the soluble Aβ assemblies present at the ages tested compared to the APP/PS1 lines (APPPS1+ 
mice were used at 2-4 months of age and J20 mice were 6-8 months old). In support of this 
hypothesis, a later study in the APPPS1+ mice showed some PrP-dependent effects at 14 months 
when soluble Aβ assemblies, including SDS-stable dimers, become abundant (38). Another well-
studied model, the Tg2576 (APPswe with PrP promoter) mouse (39), was recently shown to contain a 
sub-population of PrP binding Aβ assemblies and displayed a partial recovery of Morris Water Maze 
deficits when PrP was not expressed (40). It is known that J20 mice do not develop large pools of 
soluble Aβ oligomers until 16 months of age (41) and it may be that PrP-dependent effects are 
observed at this age if they are not overwhelmed by pre-existing PrP-independent effects. In 
addition, J20-derived Aβ oligomers are mainly recognised by the conformation-specific antibody A11 
(42) while Aβ oligomers shown to bind PrP (43) contain in-register parallel β sheets, recognised by 
the OC antibody (44). It is not known which, if any, of these models better mimic Aβ pathology in AD. 
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However, confirmation of the involvement of specific proteins in human AD should help select more 
disease-relevant animal models that may in turn benefit AD research and drug discovery. The 
corresponding authors of the first two papers reporting PrP-independent Aβ toxicity (26;35) have 
since reported PrP-dependent effects in these models (38;45), suggesting that a consensus may be 
forming (Table 1). 
One study directly contradicted the key finding of the original study (23) – that the inhibition of LTP 
by Aβ oligomers was PrP-dependent. Kessels et al. produced Aβ following the same protocol, but the 
inhibition of LTP appeared to be PrP-independent (46). In response Lauren et al. questioned the 
similarity of the Aβ preparations that were only characterised by SDS-PAGE (47). Although SDS-PAGE 
has been shown to not reliably represent Aβ assemblies present in solution (10), the contradictory 
studies highlight one problem with studies using synthetic preparations: how do we determine 
which assemblies are most relevant to the human condition? 
Independent confirmation of PrP-dependent toxicity 
It was crucial to discover whether synthetic Aβ oligomers could be produced that mimicked the most 
disease relevant forms of Aβ – those found in the brains of human AD patients that are known to 
inhibit LTP (48). Like some synthetic Aβ oligomers, those purified from AD brain inhibited LTP in wild-
type and not PrP-null mice, confirming some relevance to human AD (49). Surprisingly, a range of 
antibodies that bind close to helix-1 of PrP also effectively blocked the interaction, even though it is 
located on the opposite side of the structured domain of PrPC from residue 95-105 (Figure 2). 
Antibodies that bind to 95-105 and helix-1 of PrP, and which are known to be therapeutically active 
in prion infection (50), were found to block Aβ-induced inhibition of LTP in both murine brain slices 
and live rats (49;51). The ability of helix-1 antibodies to block Aβ-induced electrophysiological 
deficits has now been replicated in a cell-based system (52). Previously discovered PrP ligands should 
now be retested for their ability to disrupt the PrP:Aβ interaction and their potential as AD 
therapeutics assessed. Indeed, it may be that the identification of the PrP:Aβ interaction may 
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reinvigorate studies to identify small molecules that bind to PrPC and arrest prion propagation (53). 
This is firstly because of the increased interest in PrP-binding molecules as possible inhibitors of Aβ 
and, secondly, from a practical point-of-view, because it is challenging to identify PrP-binding 
molecules in high-throughput assays. Showing that a compound can block the PrP:Aβ interaction 
appears to be an acceptable surrogate for identifying molecules that bind to certain sites on PrP 
(54). 
The Aβ:PrP interaction 
Characterising the PrP binding mode 
The fact that there now appears to be a consensus on Aβ:PrP binding does not mean it is a simple 
interaction; it should not be considered a canonical binary interaction between a PrP monomer and 
a discreet Aβ oligomer. A single oligomer has the potential to interact with multiple PrP molecules 
and this could result in further conformational changes to either PrP or Aβ. Kinetic analysis 
confirmed that the interaction is effectively irreversible on a surface meaning dissociation constants 
cannot be calculated (55), whilst the slow rate of binding observed may be indicative of a 
conformational change or further Aβ aggregation in situ (55). The mechanism for helix-1 antibody-
mediated inhibition of synaptotoxicity remains obscure (49), but hints towards the involvement of 
multiple PrP molecules (49) or a rearrangement of this helix during binding (53). A number of groups 
have suggested a second positively-charged site at the extreme N-terminus of PrP (45;55), but it is 
unclear if this is truly independent or what its relevance is at pathophysiologically pertinent 
concentration. The basis of the interaction has so far not been resolved at a single amino acid level 
(45). That PrP can disassemble Aβ amyloid fibrils (56) and inhibit the assembly of Aβ into toxic 
oligomeric forms (57) at micromolar concentrations confirms the interaction, whilst selective, is not 
specific at higher concentrations. 
Identifying PrP-binding Aβ assemblies 
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It is known that PrP does not bind as strongly to Aβ monomer or mature fibrils (26;55), but 
numerous synthetic Aβ assemblies have been reported (Figure 1) (9), some of which may only vary 
in their means of preparation rather than their actual composition. Aggregation of ADDL-like 
preparations for different time periods and then characterising the Aβ assemblies present at 
different time points allowed the identification of forms that most avidly bind to PrP, as well as 
those that cause PrP-dependent or PrP-independent synaptotoxicity (43). The presence of Aβ 
protofibrils correlated better with PrP binding than either globular oligomers or amyloid fibrils. 
Crucially, globular oligomers present at initial time points failed to inhibit LTP, whereas LTP was 
significantly reduced throughout a time window where protofibrils were present. The protofibrils are 
not simply chains of globular oligomers, but contain a defined triple helical nanotube structure that 
could relate to their specific PrP-dependent toxicity (Figure 3). Could the Aβ species in AD brain that 
cause PrP-dependent toxicity be structurally related to Aβ nanotubes? The presence of SDS-stable 
dimers in post-mortem brain is strongly associated with AD (3) and PrP-dependent toxicity in mice 
(38), whilst synthetic Aβ dimers are known to favour synaptotoxic protofibril formation (58). 
Therefore, it seems plausible that structures similar to Aβ nanotubes can cause PrP-dependent 
synaptotoxicity in AD brain; although this hypothesis is yet to be tested experimentally. Several 
studies have, however, compared the PrP binding of different AD brain-derived Aβ species, 
separated by the hydrodynamic radii using size-exclusion chromatography, but none have confirmed 
if these species are toxic. Two independent studies have suggested large soluble assemblies with 
apparent molecular weights greater than 600,000 are the major PrP binding species (40;59;60), with 
a third suggesting SDS-stable dimers are the major PrP binding species (38). All this is consistent with 
a protofibrillar assembly, although this will remain speculation until such species are isolated from 
AD brain, structurally characterised and shown to cause PrP-dependent toxicity. 
PrP-dependent toxic mechanisms 
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Clearly not all Aβ toxicity is governed by PrP (Table 1) and assemblies can display distinct toxicities in 
different systems; for example, inhibition of LTP compared with cell membrane disruption (43). 
Furthermore, a variety of non-mammalian protein aggregates induce PrP-dependent cytotoxicity in 
cellular systems (61). Toxicity is mediated through the unstructured N-terminal portion of PrP 
suggesting some mechanistic overlap with toxic PrP and Aβ species. Such toxicity, caused by 
interactions with the N-terminus of PrP, yet blocked by ligands binding to the 95-105 or helix-1 
regions of PrP, is in contrast to reports of anti-PrP antibody-related toxicity caused by interaction 
with C-terminal regions of PrP and prevented by ligands binding the N-terminus (62). The apparent 
mechanistic differences between Aβ-induced and anti-PrP antibody-induced toxicity could be 
explained by the method of incubation. Anti-PrP antibody toxicity was reported after their 
incubation with brain slices prepared from transgenic mice with a high level of PrP expression for 
several weeks at high, micromolar concentrations – ~10,000 times those required to engage PrP – 
suggesting there may be non-specific toxic effects. This effect also appears inconsistent with absence 
of toxicity seen in vivo when up to two micrograms of multiple anti-PrP antibodies are directly 
injected into the hippocampi of live mice (63). Subsequent titration to 6 micrograms of PrP mAbs 
(64), injected directly into brain tissue (estimated volume of distribution 5 mm3), did however result 
in apoptosis at the cannula site. As for the brain slice experiments, dose and concentrations in these 
mouse experiments are high relative to those which might reasonably be expected to be 
therapeutically relevant. For example, Song et al. infused a PrP mAb at 1 microgram/hr into mouse 
lateral ventricle (estimated volume of distribution 500 mm3) with clinical benefits against prion 
disease and no adverse clinical or pathological events (65), implying an approximately two-log dose 
therapeutic window by comparison with Reimann et al.’s toxicity. Ohsawa et al. demonstrated some 
evidence of therapeutic potential for established mouse prion disease by peripheral injections of PrP 
mAb, with no adverse events (66). Klyubin et al. showed that intravascular injections of PrP mAb 
were able to block the effects of Aβ on LTP without adverse events (67). This paper also reported the 
single ascending dose study of PrP mAb PRN100 in cynomolgus monkey at intravenous doses up to 
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200 mg/kg, achieving serum concentrations of 5 mg/ml without significant adverse events (67). 
Overall, these studies suggest that anti-PrP antibodies have a relatively low acute neurotoxicity at 
likely therapeutic concentrations for prion infection (65-67). 
Whilst blocking the PrP:Aβ interaction, or the formation of toxic assemblies, appear to be valid 
approaches to combatting Aβ toxicity, it is also important to understand the cellular mechanisms 
and how they might be targeted pharmacologically. Identifying whether the binding of a specific Aβ 
isoform to PrP inhibits a physiological function or triggers a dysfunctional pathway is crucial to drug 
discovery strategies.  
PrP-dependent downstream mediators of toxicity 
Phosphorylation of NMDA receptors and their subsequent relocalisation is induced by Fyn activation 
(30). Of all post-synaptic density membrane proteins tested, only mGluR5-dependent Fyn activation 
was increased by Aβ oligomers (68). Formation of this complex may explain the observed clustering 
of mGluR5 at synapses in the presence of Aβ oligomers (68;69). The role of mGluR5 in PrP-
dependent Aβ toxicity has now been confirmed in the classic synaptic plasticity paradigm, inhibition 
of LTP, as well as in the associated facilitation of long-term depression (LTD) (70). It is possible that 
the PrP:mGluR5R interaction includes helix-1 of PrP (60) meaning that antibodies that bind helix-1 of 
PrP could disrupt this complex and have a secondary protective mechanism beyond directly 
inhibiting the PrP:Aβ interaction. Such serendipity should perhaps be expected in the crowded 
environment of the synapse. The Aβ:PrP:mGluR5 complex is probably the most studied and 
independently validated Aβ:PrP pathway and, importantly, its toxicity has been shown to be driven 
by AD brain extracts (30;38;68;70). PrP is linked to Homer1b/c, protein-tyrosine kinase 2β (PTK2B, 
Pyk2) and calcium/calmodulin-dependent protein Kinase II (CamKII) through mGluR5 in a Aβ-
regulated manner (13) (71). In light of these results, it will be important to examine in more detail 
the physiological function of PrP:mGluR5 in order to assess the full toxic effect of Aβ oligomers on 
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synaptic plasticity. It is possible that as well as activating toxic cascades through PrP, Aβ oligomers 
also alter PrP:mGluR5 interactions crucial for a correct functioning of the synapse. 
One effect of PrP may be to increase the local concentration of Aβ or other protein aggregates (61) 
and initiate toxic pathways that it does not directly participate in. PrP could conceivably facilitate the 
conversion of other Aβ assemblies into those that cause PrP-dependent toxicity (56). Likewise anti-
PrP antibodies could sterically block interactions with other Aβ-binding proteins closely packed 
within the synaptic membrane or block access of fibrillar Aβ assemblies that do not exert toxicity 
through PrP. More targeted site-directed mutagenesis studies where the PrP:ligand interaction is 
retained yet toxicities are specifically blocked will be required to distinguish between these 
possibilities. 
Other Aβ acceptors 
Aβ toxicity through other interacting proteins 
Numerous Aβ oligomer binding proteins have since been identified (72;73) and most of them localise 
at the synapse, suggesting that binding of Aβ assemblies may cause synaptic dysfunction at least in 
part by blocking their function. Of course many macromolecules have been shown to bind to some 
form of Aβ including: GluN1 (69;74), GluR2 (75), α7nAchR (76), RAGE (77), insulin receptor (78), 
p75NTR (79;80), β2ARs (81), Fz Wnt receptor (82), NL1 (83), reelin (84), GM1 ganglioside (85) and LRP1 
(86). 
Although only PrP was identified by an unbiased direct binding assay, two other Aβ oligomer 
acceptors were recently identified using unbiased functional screening or expression approaches: 
FcγRIIb (31)(87) and PGRMC1 (32;33) (88). Aβ oligomers also bind EphB2 (27;29)(89). As Eph 
receptors regulate plasticity and synaptic function, it would not be surprising if more members of 
the family are involved in AD (90). PirB and its human orthologue were also reported as possible Aβ 
oligomer acceptors (28). Finally, NAKα3 binds to patient-derived amylospheroids (34). Detailed 
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discussion of these receptors falls outside the bounds of this review. The heterogeneity in the 
properties of this small group of recently identified candidates highlights the difficulty in reproducing 
experiments between labs. Simply acquiring the expertise and reagents required to study one of 
these proteins and reproducing published experiments could take as long as a standard PhD project. 
Prioritising which of these acceptors is most relevant for slowing the progress of heterogeneous 
diseases such as Alzheimer's will be an enormous challenge. 
 
Why might so many receptors be involved in a single disease? Of course there will no doubt be “false 
positives”, but it is also likely that certain acceptors cause toxicity at different stages – 
presymptomatic, mild cognitive impairment, early and more advanced AD – as the different 
aggregates of Aβ accumulate and form in the brain. It is crucial to characterise the Aβ assemblies 
that bind each protein and their apparent affinity, together with any overlap in the downstream 
cascade they activate.  
Synaptic loss occurs at early stages in AD, therefore protecting, maintaining and restoring the 
structure of the synapse  could be central to AD therapy (90;91). Several neurotoxic cascades that 
are triggered by Aβ:PrP in complex with other proteins, including LRP1, cytoplasmic phospholipase 
A2 (cPLA2) and mGluR5, have been described to require lipid rafts organisation (5;30;92;93). 
Interestingly, these results agree with a suggested function for PrP as a scaffold protein on lipid rafts: 
organising proteins in a complex (94). Therefore, finding the scaffold proteins and necessary 
partners for the different receptors could identify relevant targets to develop therapies. A real 
challenge of targeting the above receptors is that complete inhibition of a receptor could be 
detrimental; therefore modulating their function back to physiological levels may be essential. 
Future Focus 
After initial scepticism and controversy the PrP:Aβ interaction is now becoming accepted as a 
significant player in Aβ-mediated toxicity in vitro and in vivo. Its high affinity has not been disputed 
and the molecular basis of this complex interaction is now being unravelled. Care needs to be taken 
Page 14 of 28 
 
to ensure experiments are carried out under the most physiological conditions possible and are 
described in such a way that they can be faithfully reproduced. More details of the structural basis of 
the interaction and mechanisms of neurotoxicity, and concrete explanations for reported 
discrepancies between publications, are required to truly understand the phenomenon. It would aid 
the field if researchers reported both positive and negative results together to help establish the 
reasons for PrP-dependent and PrP-independent toxicity. If the hypothesis that PrP is involved in AD 
cannot be falsified then experimental medicine studies could be considered. The relevance of this 
interaction to the clinical features and progression of human AD can only be firmly established 
through clinical trials of drug candidates that block the interaction or down-stream toxicity. This in 
turn could determine the suitability of individual animal models to AD drug discovery. A humanised 
anti-PrP monoclonal antibody has now been developed for treatment of prion disease and a 
preclinical study in live rats demonstrated that intravascular administration of this antibody can 
block Aβ-induced inhibition of synaptic plasticity without causing acute toxicity (67), suggesting it 
might be suitable for clinical trials in AD should it have a satisfactory safety profile. Likewise, a phase 
1b study for a potent inhibitor of src family of kinases, including Fyn, has recently been completed 
(95;96) with a phase IIa trial currently underway. Confirmation of efficacy in human trials would 
firmly establish a role for PrPC in AD. It is unlikely that any therapeutic would reverse all symptoms in 
AD patients, but blocking acute synaptotoxic effects may have an immediate measurable effect in 
memory and cognitive function. The second question of whether this then slowed rates of 
neurodegeneration would require major clinical trials. A confirmed disease-modifying therapeutic in 
the AD field would be a huge step forward after so many disappointments. While the PrP:Aβ 
interaction was only identified a few years ago, direct examination of its true relevance to AD via 
experimental medicine may hopefully not be too far away. 
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Figure 1: Diagram depicting the variety of aggregation states of Aβ and sizes. Green lines represent 
bands in gels, orange structures represent those captured by Atomic Force Microscopy (AFM) and 
black structures represent those captured by Electron Microscopy (EM). The y-axis identifies the 
name of the preparation and, where relevant identifies the source. ADDLs are “amyloid-β-derived 
diffusible ligand”, TABFOs are “amyloid-β1–42 fibrillar oligomers”. 
 
Figure 2: Modelled structure of PrPC highlighting the Aβ binding site (red) and Helix-1 (yellow). 
Amino acids in the region 95-105 are required for the interaction and antibodies raised against these 
epitopes (red and yellow) block the toxic effect of Aβ oligomers on LTP. 
 
Figure 3: Possible PrPC-dependent (left) and PrPC-independent pathways (right) for Aβ toxicity as 
well as possible functional roles for PrPC in Aβ processing, signalling and transport (centre). Aβ 
species, such as Aβ nanotubes, are known to bind directly to PrPC and induce toxicity and several, 
possibly interconnected, pathways have been identified. The PrPC:Aβ complex may directly interact 
with downstream acceptors or PrPC may raise the local concentrations of certain forms of Aβ 
thereby sensitising acceptors to Aβ toxicity. 
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Reference 
Direct Aβ:PrPC interaction Aβ:PrPC toxicity 
Comment 
Aβ source Quantitative Aβ source 
System 
assayed 
Lauren et al. 
(23) 
Synth Y Synth Cell 
Aβ:PrPC binding in cells and effect on 
LTP is PrPC-dependent 
Balducci et 
al. (26) 
Synth N Synth 
Cell, Mouse 
in vivo 
Direct Aβ:PrPC binding, but no toxicity 





Ablation of PrPC reverses cognitive 
deficits, lifetime and cell death in 
APPswe/PS1ΔE9 mouse 
Chen et al. 
(55) 
Synth N  - 
Confirmation of direct binding of Aβ 
oligomers to huPrPC 
Calella et al. 
(35) 
Synth N Mouse 
Mouse in 
vivo 
Confirmation of Aβ:PrPC interaction, but 
disputes PrPC-dependent behavioural 
effects in APPswe/PS1L166P mouse 
Kessels et al. 
(46) 
-  Cell 
Mouse ex 
vivo 
Disputes PrPC-dependent Aβ-induced 
LTP inhibition, however, uses ill-defined 
Aβ oligomers 
Lauren et al. 
(47)  
  - Reply to Kessels et al. 





Anti-PrP mAb reverses behavioural 
effects in APPswe/PS1ΔE9 mouse 
Resenberger 
et al. (61) 
Cell N  Cell 
PrPC-dependent toxicity of Aβ and 
amyloid peptides in cells 




N  - 
Aβ mainly interacts with insoluble PrPC 
in APPswe/ind mice 
Barry et al. 
(51)  
 Human Rat in vivo 
Anti-PrPC mAb reverses effect on AD 
brain extract-induced LTP inhibition 






vivo, rat in 
vivo 
Two anti-PrPC mAbs reverse Aβ-induced 
LTP defects in rats and mice 






electrophysiological and lifetime effects 
in APPswe/ind mice 
Bate et al. 
(93) 
Cell N Cell Cell 
Initial report of PrPC-dependence of 
synapse damage via cPLA2 
Alier et al. 
(52)  
 Synth Cell 
PrPC-dependent electrophysiological 
effects of Aβ in cells 
Caetano et 
al. (102) 
Synth N Synth Cell Aβ increases PrPC at the cell surface 





PrPC-dependent neuronal death in vivo 
You et al. 
(104)  
 Synth  Cell 
Interaction between copper, PrPC, Aβ 
oligomers and NMDAr 
Pflanzner et 
al. (15) 
Synth Y Synth Cell 
PrPC-dependent Aβ1-40 transcytosis 
across the BBB 
Guillot-







N1 fragment protects against Aβ-
associated cell death 
Hyeon et al. 
(105) 
Synth N Synth Cell PrPC-dependent apoptotic cell death 
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Cell Fyn dependent toxicity via NMDAR 





Overexpression of PrPC protects against 
Aβ1-40 apoptosis 
Nieznanski 
et al. (57) 
Synth N  
 
PrPC N1 fragment inhibits Aβ oligomer 
formation 











Synth Y Synth 
Cell, Mouse 
in vivo 
PrPC prevents aggregation and 
disaggregates Aβ fibrils 
Fluharty et 
al. (45) 
Synth N  
 
PrPC-based peptides deactivate Aβ 
oligomers 
Rushworth 
et al. (92) 
Synth N Synth Cell 
Role of lipid rafts and LRP-1 in PrPC-




  Mouse 
Mouse in 
vivo 
Confirmation of PrPC-dependent Aβ 
toxicity in APPswe/PS1ΔE9 mouse 
Chen et al. 
(108) 
Synth N Synth Cell Confirmation of Fyn activation 









mGluR5 as coupling receptor between 
PrPC and Fyn 
Nicoll et al. 
(43) 
Synth N Synth 
Mouse ex 
vivo 
Aβ nanotubes correlate with PrPC-
dependent inhibition of LTP 
Ostapchenk
o et al. (109) 
Synth N Synth Cell STI1 blocks Aβ binding to PrPC 
Rubel et al. 
(110) 
Synth N   
Confirmation of main binding site for 
the interaction Aβ:PrPC 





Rat in vivo Role of exosomes 
Nah et al. 
(112) 
  Synth Cell 
Aβ-induced autophagy mediated by 
presence of PrPC 
Rushworth 





Fragment of PrPC used as biosensor 






PrPC binds to large Aβ species in AD 
brain 





Rat in vivo 
PrPC:mGluR5 in Aβ-induced LTD 
facilitation and LTP inhibition 
Beland et al. 
(16) 
Human N Cell Cell 
Secreted PrPC trap Aβ in amorphous 
aggregates 
Klyubin et al. 
(67) 
Synth Y Human Rat in vivo 
Intravascular administration of anti-PrPC 
antibody 




N   
Confirmation of interaction between 
PrPC and mGluR5 
Ganzinger et 
al. (114) 
Synth Y Synth Cell 
Confirmation of Aβ:PrPC interaction by 
single molecule imaging 
Peters et al. 
(115) 
Synth N Synth Cell 
PrPC-dependent membrane damage and 
synaptotoxicity 
West et al. 
(116) 
Cell N Cell Cell 
Monoacylated PrPC binds synaptotoxic 
Aβ oligomers 
Risse et al. 
(54) 
Synth Y   
Disruption of Aβ:PrPC interaction by 
small molecule. 
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Table 1: Summary of publications demonstrating a direct interaction between PrPc and Aβ 
(quantitative or not) specifying the source of Aβ oligomers used and also those that reported PrPc-
dependent toxicity (green) and PrPc-independent toxicity (red), stating source of Aβ oligomers and 
systems employed. Synth, synthetic. 
  







Downstream signalling cascade for 
Aβ:PrPC:mGluR5 
Falker et al. 
(19) 
Synth N Synth Cell Protective role of exosomes 
Williams et 
al. (117) 
Synth N   











PrPC interacts with a pool of soluble 
high molecular weight Aβ to induce 
PrPC-dependent cognitive defects 
De Mario et 
al. (118) 
  Synth Cell 
Effect of Aβ:PrPC complex on store-
operated Ca+2 entry via Fyn 
Heiss et al. 
(119) 
Mouse Y Mouse Mouse 




Synth N Synth 
Cell, Mouse 
in vivo 




Synth N Synth Cell 
Reverses Aβ:PrPC cytotoxicity by LRP/LR 
antibody 
Haas et al. 
(71) 
  Synth 
Mouse ex 
vivo 




  Synth Zebrafish 





  Synth 
Cell, Mouse 
ex vivo 
Reverses Aβ-induced  synaptic plasticity 
impairment by PrPC fragments 
Haas et al. 
(123) 
  Synth Cell, Mouse 
Reverses AD mouse phenotypes by 
mGluR5 selective blocker 
Nolan et al. 
(124) 
  Cell Cell 
Role of the glycosylphosphatidylinositol 
(GPI) anchor attached to PrPC 
West et al. 
(125) 
  Human Cell 
Cholesterol ester cycle regulates 
Aβ:PrPC complex 
Zhang et al. 
(126) 
  Synth, Rat Rat in vivo 
Repetitive anti-PrPC antibody 
administration reverses Aβ-induced 
synaptic plasticity defects on 
longitudinal studies 
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